is co-chair of Lowenstein Sandler’s Antitrust Group and a member of the firm’s Tech Group. His 35+ years of government and private practice experience, gives Jeff in-depth knowledge of competition principles, technology, regulations, and economics across a range of industries.
For more information or to contact Jeffrey, please visit his Firm Profile Page.
The novel coronavirus pandemic has upended our lives, creating a far-from-normal “new normal.” And it has also given rise to countless collaborations between and among universities, hospitals, medical centers, pharma companies and others to pool their talent and resources to discover, test, manufacture and distribute diagnostics, treatments, vaccines, personal protective equipment and other resources needed to fight the pandemic. Antitrust law poses no risk to these collaborations, so long as they remain focused on their core missions. But at the same time, antitrust law recognizes that in cooperating and exchanging information and insights for those missions there is the potential for “spill-over effects” that can create antitrust risk. The trick is to know where that dividing line is and to avoid crossing over it.